Endpoints Shorts: Dr. Nadia Sethi on MedicNova's Ibudilast Clinical Trial

<p>Welcome to the latest episode of Endpoints Shorts, presented by the ALS Therapy Development Institute.</p> <p>In these bite-size podcasts, we’ll be tackling important scientific concepts for people interested in ALS research, current clinical trials, and news from around the ALS space ­– all in 15 minutes or less.</p> <p>Our guide throughout this series will be Dr. Nadia Sethi, ALS TDI’s Director of Community Outreach and Engagement. Today, Nadia joins us to talk about MedicNova’s phase 2/3 trial for Ibudilast.</p><p><a href="https://www.als.net/donate/" rel="payment">Support the show: https://www.als.net/donate/</a></p><p>See <a href="https://omnystudio.com/listener">omnystudio.com/listener</a> for privacy information.</p>